Projects and Support

Our lab is currently funded by federal and private sources including the Department of Defense, National Institutes of Health, and GlaxoSmithKline.

Ongoing Research Support:

2015/09/30-2020/09/29
1R01 NS091329-01, National Institute of Neurological Disorders and Stroke (NINDS)
Abisambra, Jose Francisco (PI)
PERK as a central mediator of neurotoxicity in tauopathies
The goal of this project is to determine the impact of PERK on inducing neuronal dysfunction and perpetuating pathological tau production in tauopathies.
Role: PI

2015/09/01-2018/09/30
GRANT11811993, Department of Defense
Abisambra, Jose Francisco (PI)
The impact of PERK on post-traumatic tauopathy in Alzheimer’s disease
The goal of this project is to determine the mechanistic role of PERK activation in tau pathogenesis in response to traumatic brain injury (TBI).
Role: PI

2015/04/28-2017/04/28
Contract, GlaxoSmithKline
Abisambra, Jose Francisco (PI)
PERK inhibition as a therapeutic strategy for Alzheimer’s disease
The goal of this project is to determine the impact of chemically inhibiting PERK in tau transgenic mice before deposition of tau tangles
Role: PI

2015/04/28-2017/04/27
5P30GM110787, National Institute of General Medical Sciences (NIGMS)
Hersh, Louis (PI)
Pilot Project: PERK inhibition for traumatic brain injury therapeutics
The goal of this project is determine the effect of PERK inhibition on TBI outcome in wild type and PERK conditional knockout mice
Role: Pilot Project PI

2015/06/01-2016/12/01
5UL1TR000117-04, National Center for Advancing Translational Sciences (NIH/NCATS)
Kern, Philip (PI)
Pilot Project: Innovation and High Impact Award
Manganese-enhanced MRI detection of neuronal dysfunction in pre-symptomatic tauopathy
The goal of this project is to develop ME-MRI with T1 parametric mapping with Teslascan, an FDA-approved manganese compound.
Role: Pilot Project PI

2015/02/01-2017/01/13
NIRG-14-322441, Alzheimer's Association
Abisambra, Jose Francisco (PI)
The impact of the tau-rpS6 association in the pathogenesis of Alzheimer’s disease
The goal of this study is to characterize the functional consequences of the relationship between tau and the ribosomal protein S6.
Role: PI

Completed Research Support:

07/01/13-06/30/14
5P30AG028383-00, National Institute on Aging (NIA)
Van Eldik, Linda (PI)
ADC Pilot Grant: Head injury-induced tauopathy: role of proteotoxic phospho-tau intermediates. The goal of this project is to identify the pathological contribution of tau in head injury and its accuracy as a biomarker for chronic traumatic encephalopathy.
Role: Pilot Project PI

10/01/12-09/30/14
NIRGD-12-242642, Alzheimer's Association
Abisambra, Jose Francisco (PI)
Mechanism of tau and ER stress for novel Alzheimer’s disease therapeutics
This study identified a pathological mechanism linking tau and ER stress in Alzheimer’s disease.
Role: PI

06/01/12-05/31/13
6144107400, CurePSP
Abisambra, Jose Francisco (co-PI), Dickey, Chad Anthony (co-PI)
Mechanisms of tau and ER stress for novel PSP and CBD therapeutics
This study identified a link between tau and PERK, a risk factor for PSP.
Role: co-PI